ADMA Biologics, Inc.
ADMA
$8.41
$0.536.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.73% | 3.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.73% | 3.68% | |||
| Cost of Revenue | -32.98% | -14.08% | |||
| Gross Profit | -9.08% | 17.44% | |||
| SG&A Expenses | 12.85% | 6.90% | |||
| Depreciation & Amortization | 7.84% | 34.21% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.98% | -8.17% | |||
| Operating Income | -19.85% | 23.01% | |||
| Income Before Tax | -7.25% | 29.63% | |||
| Income Tax Expenses | -3.41% | 10.18% | |||
| Earnings from Continuing Operations | -8.20% | 35.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.20% | 35.55% | |||
| EBIT | -19.85% | 23.01% | |||
| EBITDA | -19.54% | 22.18% | |||
| EPS Basic | -7.47% | 35.89% | |||
| Normalized Basic EPS | -19.59% | 24.27% | |||
| EPS Diluted | -4.95% | 33.27% | |||
| Normalized Diluted EPS | -18.94% | 24.43% | |||
| Average Basic Shares Outstanding | -0.80% | -0.26% | |||
| Average Diluted Shares Outstanding | -1.60% | -0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||